	US 11,872,257 B2
	Saccharomyces boulardii for the treatment of mood disorders
Emmanuelle Simon O'Brien, Lacroix-Saint-Ouen (FR); Marc Verleye, Remy (FR); and Marie-Emmanuelle Le Guern, Compiegne (FR)
Assigned to BIOCODEX, Gentilly (FR)
Appl. No. 16/638,290
Filed by BIOCODEX, Gentilly (FR)
PCT Filed Aug. 10, 2018, PCT No. PCT/EP2018/071726 § 371(c)(1), (2) Date Feb. 11, 2020, PCT Pub. No. WO2019/030371, PCT Pub. Date Feb. 14, 2019.
Claims priority of application No. 17306065 (EP), filed on Aug. 11, 2017.
Prior Publication US 2020/0179469 A1, Jun. 11, 2020
Int. Cl. A61K 36/064 (2006.01); A61P 25/22 (2006.01); A61P 25/24 (2006.01); A61K 9/00 (2006.01); A61K 9/19 (2006.01)

CPC A61K 36/064 (2013.01) [A61K 9/0053 (2013.01); A61K 9/19 (2013.01); A61P 25/22 (2018.01); A61P 25/24 (2018.01)]

19 Claims

1. A method for treating mood disorders in an individual in need thereof comprising

selecting an individual having a mood disorder, wherein the mood disorder is a depressive disorder, depression, an anxious disorder, or an anxiety disorder; and

administering an effective amount of Saccharomyces boulardii yeast cells to said individual, wherein Saccharomyces boulardii yeast cells are not administered with another anxiolytic or antidepressant substance or with Bifidobacterium longum, and where a majority of the Saccharomyces boulardii yeast cells are viable.